← Product Code [NBC](/submissions/CH/subpart-b%E2%80%94clinical-chemistry-test-systems/NBC) · K030286 # TRIAGE CARDIO PROFILER/TRIAGE CARDIAC PANEL (K030286) _Biosite Incorporated · NBC · Feb 21, 2003 · Clinical Chemistry · SESE_ **Canonical URL:** https://fda.innolitics.com/submissions/CH/subpart-b%E2%80%94clinical-chemistry-test-systems/NBC/K030286 ## Device Facts - **Applicant:** Biosite Incorporated - **Product Code:** [NBC](/submissions/CH/subpart-b%E2%80%94clinical-chemistry-test-systems/NBC.md) - **Decision Date:** Feb 21, 2003 - **Decision:** SESE - **Submission Type:** Special - **Regulation:** 21 CFR 862.1117 - **Device Class:** Class 2 - **Review Panel:** Clinical Chemistry ## Indications for Use The Triage® Cardio ProfilER is a fluorescence immunoassay to be used with the Triage® Meter for the quantitative determination of Creatine Kinase MB. myoglobin, troponin I, and B-type natriuretic peptide in EDTA whole blood and plasma specimens. The test is used as an aid in the diagnosis of myocardial infarction (injury), the diagnosis and assessment of severity of congestive heart failure (also referred to as heart failure), and the risk stratification of patients with acute coronary syndromes. The Triage® Cardiac Panel is a fluorescence immunoassay to be used with the Triage® Meter for the quantitative determination of Creatine Kinase MB, myoglobin and troponin I in EDTA whole blood and plasma specimens. The test is used as an aid in the diagnesis of myocardial infarction (injury). ## Device Story Fluorescence immunoassay system; utilizes Triage® Meter to measure Creatine Kinase MB, myoglobin, troponin I, and B-type natriuretic peptide (BNP) in EDTA whole blood or plasma. Device combines functionality of previous cardiac panels; provides quantitative results to clinicians to aid in diagnosis of myocardial infarction, assessment of heart failure severity, and risk stratification for acute coronary syndromes. Used in clinical settings; results inform immediate clinical decision-making regarding cardiac injury and heart failure management. ## Clinical Evidence No clinical data provided; substantial equivalence based on analytical performance comparison to predicate devices. ## Technological Characteristics Fluorescence immunoassay; quantitative measurement of cardiac biomarkers. Uses Triage® Meter for signal detection. Specimens: EDTA whole blood or plasma. System is a combination of previously cleared immunoassay technologies. ## Regulatory Identification The B-type natriuretic peptide (BNP) test system is an in vitro diagnostic device intended to measure BNP in whole blood and plasma. Measurements of BNP are used as an aid in the diagnosis of patients with congestive heart failure. ## Special Controls *Classification.* Class II (special controls). The special control is “Class II Special Control Guidance Document for B-Type Natriuretic Peptide Premarket Notifications; Final Guidance for Industry and FDA Reviewers.” ## Predicate Devices - Triage® Cardiac Panel ([K973126](/device/K973126.md)) - Triage® BNP Test ([K021317](/device/K021317.md)) ## Submission Summary (Full Text) > This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com. > > Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/). {0}------------------------------------------------ ## 510(k) Summary of Safety and Effectiveness # Ko 70286 # Triage® Cardio ProfilER / Triage® Cardiac Panel FEB 2 1 2003 This 510(k) summary of safety and effectiveness is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92. #### 510(k) Number: (To be determined) ### A. Name and Address of Submitter | Company Name: | Biosite Incorporated | |------------------------|--------------------------| | Address: | 11030 Roselle Street | | | San Diego, CA 92121 | | Telephone: | (858) 455-4808 | | Fax: | (858) 535-8350 | | Contact Person: | Jeffrey R. Dahlen, Ph.D. | | Date Summary Prepared: | 1/27/03 | ### B. Device Names - 1. Trade Name Triage® Cardio ProfilER / Triage® Cardiac Panel - 2. Common / Usual Name Triage® Cardio ProfilER / Triage® Cardiac Panel - 3. Classification Name Fluorometric Method, CPK or Isoenzymes (862.1215) Product Code JHX Immunoassay Method, Troponin Subunit (862.1215) Product Code MMI Myoglobin, Antigen, Antiserum, Control (866.5680) Product Code DDR Test, Natriuretic Peptide (862.1117) (Triage® Cardio ProfilER) Product Code NBC # C. Predicate Devices Triage® Cardiac Panel (K973126) {1}------------------------------------------------ Triage® BNP Test (K021317) #### D. Device Description and Intended Use The Triage® Cardio ProfilER is a fluorescence immunoassay to be used with the Triage® Meter for the quantitative determination of Creatine Kinase MB, myoqlobin, troponin I, and B-type natriuretic peptide in EDTA whole blood and plasma specimens. The test is used as an aid in the diagnosis of myocardial infarction (injury), the diagnosis and assessment of severity of congestive heart failure (also referred to as heart failure), and the risk stratification of patients with acute coronary syndromes. The Triage® Cardiac Panel is a fluorescence immunoassay to be used with the Triage® Meter for the quantitative determination of Creatine Kinase MB, myoglobin and troponin I in EDTA whole blood and plasma specimens. The test is used as an aid in the diagnosis of myocardial infarction (injury). ### E. Summary of Comparison Data The Triage® Cardio ProfilER is a combination of the two predicate devices. The only differences between the Triage® Cardio ProfilER and the predicate devices is that the Triage® Cardio uses EDTA as an anticoagulant, while the Triage® Cardiac Panel uses heparin as an anticoagulant, and the troponin assay has a lower analytical sensitivity than the troponin assay on the Triage® Cardiac Panel. The only difference between the modified Triage® Cardiac Panel and the Triage® Cardio ProfilER is the absense of a BNP assay on the Triage® Cardiac Panel. #### F. Conclusion The design control process led to a determination that the Triage® Cardio ProfilER and Triage® Cardiac Panel are substantially equivalent to the previously cleared predicate devices. The evaluation has led to assurance that the Triage® Cardio ProfilER and Triage® Cardiac Panel are safe and effective for their intended uses and no new issues of safety and effectiveness have been raised. {2}------------------------------------------------ Image /page/2/Picture/1 description: The image is a black and white logo for the Department of Health & Human Services. The logo is circular, with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" arranged around the top half of the circle. Inside the circle is a stylized image of an eagle's head, with three lines representing the feathers. The eagle's head is facing to the right. Food and Drug Administration 2098 Gaither Road Rockville MD 20850 FEB 2 1 2003 Jeffery R. Dahlen, Ph.D. Principal Scientist Clinical & Regulatory Affairs Biosite® Inc. 11030 Roselle Street San Diego, CA 92121 Re: k030286 Trade/Device Name: Triage® Cardio ProfilER/Triage® Cardiac Panel Regulation Number: 21 CFR 862.1215 Regulation Name: Creatine phosphokinase/creatine kinase or isoenzymes test system Regulatory Class: Class II Product Code: NBC; JHX; MMI; DDR Dated: January 27, 2003 Received: January 28, 2003 Dear Dr. Dahlen: We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration. Iisting of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820). {3}------------------------------------------------ Page 2 - This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market. If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 594-3084. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html. Sincerely yours, Steven Sutman Steven I. Gutman, M.D., M.B.A. Director Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health Enclosure {4}------------------------------------------------ Ko30286 510(k) Number (if known): (to be determined) Device Name: Triage® Cardio ProfilER / Triage® Cardiac Panel Indications For Use: The Triage® Cardio ProfilER is a fluorescence immunoassay to be used with the Triage® Meter for the quantitative determination of Creatine Kinase MB. myoglobin, troponin I, and B-type natriuretic peptide in EDTA whole blood and plasma specimens. The test is used as an aid in the diagnosis of myocardial infarction (injury), the diagnosis and assessment of severity of congestive heart failure (also referred to as heart failure), and the risk stratification of patients with acute coronary syndromes. The Triage® Cardiac Panel is a fluorescence immunoassay to be used with the Triage® Meter for the quantitative determination of Creatine Kinase MB, myoglobin and troponin I in EDTA whole blood and plasma specimens. The test is used as an aid in the diagnesis of myocardial infarction (injury). > Acan (Arabili (Division Sign-Off) Division of Clinical Laboratory Devices 510(k) Number_KO3078 (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED) Concurrence of CDRH, Office of Device Evaluation (ODE) Prescription Use V (Per 21 CFR 801.109) OR Over-The Counter Use__________________________________________________________________________________________________________________________________________________________ (Optional Format 1-2-96) --- **Source:** [https://fda.innolitics.com/submissions/CH/subpart-b%E2%80%94clinical-chemistry-test-systems/NBC/K030286](https://fda.innolitics.com/submissions/CH/subpart-b%E2%80%94clinical-chemistry-test-systems/NBC/K030286) **Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact). **Cite:** Innolitics at https://innolitics.com